.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,318,767

« Back to Dashboard

Details for Patent: 5,318,767

Title: X-ray contrast compositions useful in medical imaging
Abstract:An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmaceutically acceptable carrier therefor is useful in x-ray diagnostic medical imaging methods. The agents can be delivered to a specific tissue or fluid site, for example, the blood pool, liver or spleen. In one embodiment involving intravenous administration, preferred compositions provide effective imaging of the blood pool for remarkably long times.
Inventor(s): Liversidge; Gary G. (West Chester, PA), Cooper; Eugene R. (Berwyn, PA), Shaw; J. Michael (King of Prussia, PA), McIntire; Gregory L. (West Chester, PA)
Assignee: Sterling Winthrop Inc. (New York, NY)
Filing Date:Aug 10, 1992
Application Number:07/928,244
Claims:1. An x-ray contrast composition comprising particles consisting essentially of 99.9-10% by weight of a nonradioactive crystalline organic x-ray contrast agent having a solubility in water of less than 10 mg/ml, said x-ray contrast agent having a non-crosslinked surface modifier adsorbed on the surface thereof in an amount of 0.1-90% by weight and sufficient to maintain an effective average particle size of less than 400 nm, and a pharmaceutically acceptable carrier therefor.

2. The composition of claim 1 wherein said particles have an effective particle size of less than 300 nm.

3. The composition of claim 1 wherein said particles have an effective particle size of less than 200 nm.

4. The composition of claim 1 wherein said x-ray contrast agent is an iodinated aromatic compound.

5. The composition of claim 1 wherein said x-ray contrast agent is an ester or an amide of an iodinated aromatic acid selected from the group consisting of diatrizoic acid, metrizoic acid, iothalamic acid, trimesic acid and iodipamide.

6. The composition of claim 1 wherein said x-ray contrast agent is ethyl-3,5-diacetamido-2,4,6-triiodobenzoate.

7. The composition of claim 1 wherein said x-ray contrast agent is ethyl(3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)acetate.

8. The composition of claim 1 wherein said x-ray contrast agent is ethyl-2-(3,5-bis(acetylamino)-2,4,6triiodobenzoyloxy)butyrate.

9. The composition of claim 1 wherein said carrier is water.

10. The composition of claim 1 wherein said particles are present in an amount of 10-25% by weight.

11. The composition of claim 1 wherein said surface modifier is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine.

12. The composition of claim 1 wherein said surface modifier has the formula ##STR5## L' is a chemical bond, --O--, --S--, --NH--, --CONH-- or --SO.sub.2 NH--; R is a hydrophobic substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted aryl group;

each of R.sup.1 and R.sup.2 independently is hydrogen or an alkyl group having from 1 to 4 carbon atoms;

each of a and b independently is 0 or an integer from 1 to 3, provided that the sum of a and b is not greater than 3; and,

each of x and y independently is an integer from 3 to 7.

13. The x-ray contrast composition of claim 1 wherein said particles consist essentially of crystalline ethyl-3,5-diacetamido-2,4,6-triiodobenzoate having a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine adsorbed on the surface thereof.

14. The x-ray contrast composition of claim 1 wherein said particles consist essentially of crystals of the ethyl glycolate ester of diatrizoic acid having a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine adsorbed on the surface thereof.

15. The x-ray contrast composition of claim 1 wherein said particles consist essentially of crystalline ethyl-2-(3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)butyrate having a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine adsorbed on the surface thereof.

16. A method for medical x-ray diagnostic imaging which comprises administering to the body of a test subject an effective contrast producing amount of the x-ray contrast composition defined in claim 1.

17. The method of claim 16 wherein said surface modifier is present in an amount of 10 to 30% by weight based on the total weight of the dry particle.

18. The x-ray contrast composition of claim 1 wherein said surface modifier is a surfactant.

19. The x-ray contrast compositon of claim 1 wherein said surface modifier is a nonionic surfactant.

20. The x-ray contrast compositon of claim 1 wherein said surface modifier is a anionic surfactant.

21. The x-ray contrast composition of claim 1 wherein said surface modifier is selected from the group consisting of gelatin, casein, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetamacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, caboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, poloxomers, poloxamines, dextran, a dioctyl ester of sodium sulfosuccinic acid, sodium lauryl sulfate, and an alkyl aryl polyether sulfonate.

22. The x-ray contrast composition of claim 1 wherein said surface modifier is present in an amount of 10 to 60% by weight based on the total weight of the dry particle.

23. The x-ray contrast composition of claim 1 wherein said surface modifier is present in an amount of 10 to 30% by weight based on the total weight of the dry particle.

24. The method of claim 16 wherein said surface modifier is a surfactant.

25. The method of claim 16 wherein said surface modifier is a nonionic surfactant.

26. The method of claim 16 wherein said surface modifier is an anionic surfactant.

27. The method of claim 16 wherein said surface modifier is selected from the group consisting of gelatin, casein, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetamacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene caster oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, poloxomers, poloxamines, dextran, a dioctyl ester of sodium sulfosuccinic acid, sodium lauryl sulfate and an alkyl aryl polyether sulfonate.

28. The method of claim 16 wherein said surface modifier is present in an amount of 10 to 60% by weight based on the total weight of the dry particle.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc